Joel M Gelfand

Summary

Affiliation: University of Pennsylvania
Country: USA

Publications

  1. pmc Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting
    Joel M Gelfand
    Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA
    Arch Dermatol 148:487-94. 2012
  2. ncbi request reprint Epidemiology of psoriatic arthritis in the population of the United States
    Joel M Gelfand
    Department of Dermatology, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA 19104, USA
    J Am Acad Dermatol 53:573. 2005
  3. ncbi request reprint Risk of myocardial infarction in patients with psoriasis
    Joel M Gelfand
    Department of Dermatology and Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA 19104, USA
    JAMA 296:1735-41. 2006
  4. ncbi request reprint The risk of mortality in patients with psoriasis: results from a population-based study
    Joel M Gelfand
    MSCE, Department of Dermatology, University of Pennsylvania School of Medicine, 2 Maloney Bldg, 3600 Spruce St, Philadelphia, PA 19104, USA
    Arch Dermatol 143:1493-9. 2007
  5. ncbi request reprint The risk of lymphoma in patients with psoriasis
    Joel M Gelfand
    Department of Dermatology and Center for Clinical Epidemiology and Biostatistics University of Pennsylvania, Philadelphia, 19104, USA
    J Invest Dermatol 126:2194-201. 2006
  6. ncbi request reprint Prevalence and treatment of psoriasis in the United Kingdom: a population-based study
    Joel M Gelfand
    Center for Clinical Epidemiology and Biostatistics, and Department of Dermatology, University of Pennsylvania, 3600 Spruce Street, 2 Maloney Building, Philadelphia, PA 19104, USA
    Arch Dermatol 141:1537-41. 2005
  7. pmc The risk of stroke in patients with psoriasis
    Joel M Gelfand
    Department of Dermatology, University of Pennsylvania School of Medicine, Pennsylvania, PA 19104, USA
    J Invest Dermatol 129:2411-8. 2009
  8. ncbi request reprint The prevalence of psoriasis in African Americans: results from a population-based study
    Joel M Gelfand
    Department of Dermatology and Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, PA 19104, USA
    J Am Acad Dermatol 52:23-6. 2005
  9. pmc Psoriasis and cardiovascular risk: strength in numbers, part II
    Joel M Gelfand
    Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    J Invest Dermatol 131:1007-10. 2011
  10. pmc Psoriasis and cardiovascular risk: strength in numbers
    Joel M Gelfand
    Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    J Invest Dermatol 130:919-22. 2010

Detail Information

Publications69

  1. pmc Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting
    Joel M Gelfand
    Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA
    Arch Dermatol 148:487-94. 2012
    ..To compare the effectiveness of biologic systemic therapy, nonbiologic systemic therapy, and phototherapy for treatment of psoriasis...
  2. ncbi request reprint Epidemiology of psoriatic arthritis in the population of the United States
    Joel M Gelfand
    Department of Dermatology, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA 19104, USA
    J Am Acad Dermatol 53:573. 2005
    ..Estimates of the prevalence of psoriatic arthritis vary widely and are usually not determined by population-based studies...
  3. ncbi request reprint Risk of myocardial infarction in patients with psoriasis
    Joel M Gelfand
    Department of Dermatology and Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA 19104, USA
    JAMA 296:1735-41. 2006
    ..Psoriasis has been associated with cardiovascular diseases, but has only been investigated in hospital-based studies that did not control for major cardiovascular risk factors...
  4. ncbi request reprint The risk of mortality in patients with psoriasis: results from a population-based study
    Joel M Gelfand
    MSCE, Department of Dermatology, University of Pennsylvania School of Medicine, 2 Maloney Bldg, 3600 Spruce St, Philadelphia, PA 19104, USA
    Arch Dermatol 143:1493-9. 2007
    ..To determine the risk of mortality in patients with psoriasis...
  5. ncbi request reprint The risk of lymphoma in patients with psoriasis
    Joel M Gelfand
    Department of Dermatology and Center for Clinical Epidemiology and Biostatistics University of Pennsylvania, Philadelphia, 19104, USA
    J Invest Dermatol 126:2194-201. 2006
    ..Although patients with psoriasis have an increased relative risk of lymphoma, the absolute risk attributable to psoriasis is low given that lymphoma is a rare disease and the magnitude of association is modest...
  6. ncbi request reprint Prevalence and treatment of psoriasis in the United Kingdom: a population-based study
    Joel M Gelfand
    Center for Clinical Epidemiology and Biostatistics, and Department of Dermatology, University of Pennsylvania, 3600 Spruce Street, 2 Maloney Building, Philadelphia, PA 19104, USA
    Arch Dermatol 141:1537-41. 2005
    ..To measure the prevalence and treatment of psoriasis in the United Kingdom...
  7. pmc The risk of stroke in patients with psoriasis
    Joel M Gelfand
    Department of Dermatology, University of Pennsylvania School of Medicine, Pennsylvania, PA 19104, USA
    J Invest Dermatol 129:2411-8. 2009
    ..Patients with psoriasis, particularly if severe, have an increased risk of stroke that is not explained by major stroke risk factors identified in routine medical care...
  8. ncbi request reprint The prevalence of psoriasis in African Americans: results from a population-based study
    Joel M Gelfand
    Department of Dermatology and Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, PA 19104, USA
    J Am Acad Dermatol 52:23-6. 2005
    ..The prevalence of psoriasis in African Americans has been previously reported as rare. However, there have been no population-based studies to assess the prevalence and burden of psoriasis in African Americans...
  9. pmc Psoriasis and cardiovascular risk: strength in numbers, part II
    Joel M Gelfand
    Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    J Invest Dermatol 131:1007-10. 2011
    ....
  10. pmc Psoriasis and cardiovascular risk: strength in numbers
    Joel M Gelfand
    Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    J Invest Dermatol 130:919-22. 2010
    ..This negative result should be interpreted in light of the study's limitations, the complex relationship among levels of psoriasis severity, patient age, and cardiovascular (CV) risk, and the context of the rapidly growing literature...
  11. pmc Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis
    Howa Yeung
    Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania 19104, USA
    J Am Acad Dermatol 68:64-72. 2013
    ..Despite widespread dissatisfaction and low treatment persistence in moderate to severe psoriasis, patients' reasons behind treatment discontinuation remain poorly understood...
  12. pmc Dermatologist preferences for first-line therapy of moderate to severe psoriasis in healthy adult patients
    Joy Wan
    Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania 19104, USA
    J Am Acad Dermatol 66:376-86. 2012
    ..Despite increasing therapies for moderate to severe psoriasis, dermatologists' treatment preferences are unknown...
  13. pmc Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom
    Sinead M Langan
    Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK
    J Invest Dermatol 132:556-62. 2012
    ..These findings suggest that screening for metabolic disease should be considered for psoriasis, especially when it is severe...
  14. pmc Psoriasis severity and the prevalence of major medical comorbidity: a population-based study
    Howa Yeung
    Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia
    JAMA Dermatol 149:1173-9. 2013
    ..Despite the growing literature on comorbidity risks in psoriasis, there remains a critical knowledge gap on the degree to which objectively measured psoriasis severity may affect the prevalence of major medical comorbidity...
  15. pmc Variation in dermatologist beliefs about the safety and effectiveness of treatments for moderate to severe psoriasis
    Katrina Abuabara
    Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania 19104, USA
    J Am Acad Dermatol 68:262-9. 2013
    ..Physician perceptions can influence prescribing patterns and patient outcomes, and may help to explain variations in clinical practice...
  16. ncbi request reprint Prevalence of cardiovascular risk factors in patients with psoriasis
    Andrea L Neimann
    Dermatology, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    J Am Acad Dermatol 55:829-35. 2006
    ..Limited population-based data exist on this association, and few studies have determined which factors are independently associated with psoriasis...
  17. doi request reprint Immunosuppressant medications and mortality in inflammatory bowel disease
    James D Lewis
    Division of Gastroenterology, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    Am J Gastroenterol 103:1428-35; quiz 1436. 2008
    ..This study examined whether treatment of Crohn's disease (CD) and ulcerative colitis (UC) with immunosuppressant medications was associated with an increased risk of death in the era prior to antitumor necrosis factor (TNF) therapies...
  18. pmc Risk of moderate to advanced kidney disease in patients with psoriasis: population based cohort study
    Joy Wan
    Department of Dermatology, University of Pennsylvania, Philadelphia, PA 19104, USA
    BMJ 347:f5961. 2013
    ..To determine the risk of chronic kidney disease in patients with psoriasis...
  19. pmc Attributable risk estimate of severe psoriasis on major cardiovascular events
    Nehal N Mehta
    Preventive Cardiology, Division of Cardiovascular Medicine, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, USA
    Am J Med 124:775.e1-6. 2011
    ..We compared the risk of major adverse cardiac events between patients with psoriasis and the general population and estimated the attributable risk of severe psoriasis...
  20. pmc Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database
    Nehal N Mehta
    Cardiovascular Institute, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Eur Heart J 31:1000-6. 2010
    ..We conducted a cohort study using the General Practice Research Database to determine if severe psoriasis patients have an increased risk of cardiovascular (CV) mortality...
  21. pmc Risk of mortality in patients with psoriatic arthritis, rheumatoid arthritis and psoriasis: a longitudinal cohort study
    Alexis Ogdie
    Division of Rheumatology, Center for Clinical Epidemiology and Biostatistics, Center for Pharmacoepidemiology Research and Training, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Ann Rheum Dis 73:149-53. 2014
    ..The objective of this study was to examine the risk of mortality in patients with PsA compared with matched controls, patients with psoriasis and those with rheumatoid arthritis (RA)...
  22. pmc Increased risk of diabetes mellitus and likelihood of receiving diabetes mellitus treatment in patients with psoriasis
    Rahat S Azfar
    Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA 16104, USA
    Arch Dermatol 148:995-1000. 2012
    ..To assess the risk of incident diabetes mellitus (DM) in patients with psoriasis and to evaluate DM treatment patterns among patients with psoriasis and incident DM...
  23. ncbi request reprint Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom
    Joel M Gelfand
    Department of Dermatology and the Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadephia 19104, USA
    Arch Dermatol 139:1425-9. 2003
    ..To determine if the rate of lymphoma in patients with a history of psoriasis is different from the rate of lymphoma in patients without psoriasis...
  24. pmc The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study
    Shanu Kohli Kurd
    Department of Medicine, University of Pennsylvania, 3600 Spruce Street, Philadelphia, PA 19104, USA
    Arch Dermatol 146:891-5. 2010
    ..To determine the incidence of depression, anxiety, and suicidality in patients with psoriasis compared with the general population...
  25. ncbi request reprint Determinants of quality of life in patients with psoriasis: a study from the US population
    Joel M Gelfand
    Department of Dermatology and Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, USA
    J Am Acad Dermatol 51:704-8. 2004
    ..Psoriasis is a common disease with substantial effects on quality of life. Few quality of life studies have been performed in psoriasis patients from the general US population...
  26. pmc Is there truly a risk of lymphoma from biologic therapies?
    Erica Dommasch
    Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Dermatol Ther 22:418-30. 2009
    ..Continued vigilance is warranted; however, in the appropriate patient, the risk-to-benefit profile of psoriasis treatment with respect to lymphoma risk appears highly favorable...
  27. pmc Prevalence and treatment patterns of psoriatic arthritis in the UK
    Alexis Ogdie
    Division of Rheumatology, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, 8 Penn Tower, 1 Convention Ave, Philadelphia, PA 19104, USA
    Rheumatology (Oxford) 52:568-75. 2013
    ....
  28. pmc National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening
    Alexa B Kimball
    Department of Dermatology, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Am Acad Dermatol 58:1031-42. 2008
    ....
  29. pmc Reliability and convergent validity of the cutaneous sarcoidosis activity and morphology instrument for assessing cutaneous sarcoidosis
    Misha Rosenbach
    Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, USA
    JAMA Dermatol 149:550-6. 2013
    ....
  30. doi request reprint Exploring priority research areas in psoriasis and psoriatic arthritis from dermatologists' perspective: a report from the GRAPPA 2011 annual meeting
    April W Armstrong
    Department of Dermatology, University of California Davis, Sacramento, California 95816, USA
    J Rheumatol 39:2204-10. 2012
    ..Finally, the members supported continued efforts to explore the genetic basis of psoriasis and more studies focused on comparative effectiveness of existing treatments...
  31. pmc Abnormal lipoprotein particles and cholesterol efflux capacity in patients with psoriasis
    Nehal N Mehta
    Cardiovascular Institute, University of Pennsylvania School of Medicine, USA
    Atherosclerosis 224:218-21. 2012
    ..We sought to study how chronic in vivo inflammation modulates lipoprotein particle composition using nuclear magnetic resonance spectroscopy (NMR) and HDL efflux in psoriasis...
  32. doi request reprint Oral curcumin in the treatment of moderate to severe psoriasis vulgaris: A prospective clinical trial
    Shanu Kohli Kurd
    Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    J Am Acad Dermatol 58:625-31. 2008
    ..There is a need for safe, inexpensive, and effective psoriasis therapies. Many anecdotal accounts of patients' successful treatment with the alternative medicine curcumin exist...
  33. pmc The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials
    Erica D Dommasch
    Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    J Am Acad Dermatol 64:1035-50. 2011
    ..There is a need to better understand the safety of tumor necrosis factor (TNF) inhibitors in patients with psoriatic disease in whom TNF inhibitors are frequently used as monotherapy...
  34. pmc Metabolic syndrome in patients with psoriatic disease
    Joel M Gelfand
    Department of Dermatology and Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA
    J Rheumatol Suppl 89:24-8. 2012
    ..Further research will be necessary to establish the directionality of this association and to explore the effect of treatment on these comorbid diseases...
  35. doi request reprint Patient-reported outcomes and health-care resource utilization in patients with psoriasis treated with etanercept: continuous versus interrupted treatment
    Joel M Gelfand
    Department of Dermatology and Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, USA
    Value Health 11:400-7. 2008
    ..The objective of this analysis was to assess patient-reported outcomes (PROs) and health-care resource utilization (HRU) data from the EASE study...
  36. ncbi request reprint From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis
    Mark Lebwohl
    Department of Dermatology, Mount Sinai School of Medicine, New York, New York, USA
    J Am Acad Dermatol 58:94-105. 2008
    ..Biologics are widely used in the treatment of psoriasis and psoriatic arthritis...
  37. doi request reprint Consensus guidelines for the management of plaque psoriasis
    Sylvia Hsu
    Department of Dermatology, Baylor College of Medicine, Houston, TX 77030, USA
    Arch Dermatol 148:95-102. 2012
    ....
  38. pmc Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT): a pilot study
    Nehal N Mehta
    Cardiovascular Institute, University of Pennsylvania School of Medicine, 6 Penn Tower, Philadelphia, PA 19104, USA
    Arch Dermatol 147:1031-9. 2011
    ..To evaluate the feasibility of using [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT) to detect and quantify systemic inflammation in patients with psoriasis...
  39. doi request reprint Test characteristics of high-resolution ultrasound in the preoperative assessment of margins of basal cell and squamous cell carcinoma in patients undergoing Mohs micrographic surgery
    Anokhi Jambusaria-Pahlajani
    Department of Dermatology, University of Pennsylvannia, Philadelphia, Pennsylvania, USA
    Dermatol Surg 35:9-15; discussion 15-6. 2009
    ..Noninvasive techniques to assess subclinical spread of nonmelanoma skin cancer (NMSC) may improve surgical precision. High-resolution ultrasound has shown promise in evaluating the extent of NMSC...
  40. doi request reprint The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004
    Shanu Kohli Kurd
    Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    J Am Acad Dermatol 60:218-24. 2009
    ..Psoriasis is a predictor of morbidity. It is important to determine the extent to which psoriasis remains undiagnosed...
  41. ncbi request reprint Surrogate end points for the treatment of diabetic neuropathic foot ulcers
    David J Margolis
    Department of Dermatology and Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Diabetes Care 26:1696-700. 2003
    ....
  42. doi request reprint Evaluation of AJCC tumor staging for cutaneous squamous cell carcinoma and a proposed alternative tumor staging system
    Anokhi Jambusaria-Pahlajani
    Department of Dermatology, Mayo Clinic Florida, Jacksonville, USA
    JAMA Dermatol 149:402-10. 2013
    ..This study proposes an alternative tumor staging system for cutaneous squamous cell carcinoma (CSCC) that more precisely defines the small subset of tumors with a high risk of metastasis and death...
  43. pmc Aortic vascular inflammation in psoriasis is associated with HDL particle size and concentration: a pilot study
    Yiding Yu
    Cardiovascular Institute, University of Pennsylvania 6 Penn Tower, Philadelphia, Pennsylvania, USA
    Am J Cardiovasc Dis 2:285-92. 2012
    ..These findings suggest that HDL particle characteristics may play an important role in psoriatic vascular inflammation and CVD...
  44. doi request reprint High clinical response rate of Sezary syndrome to immunomodulatory therapies: prognostic markers of response
    Brian A Raphael
    Department of Dermatology, The Hospital at the University of Pennsylvania, Philadelphia, USA
    Arch Dermatol 147:1410-5. 2011
    ..To quantify response rates of Sézary syndrome (SS) to multimodality immunomodulatory therapy and to identify the important prognostic parameters that affect overall response to treatment...
  45. ncbi request reprint National Psoriasis Foundation clinical consensus on disease severity
    David M Pariser
    Department of Dermatology, Eastern Virginia Medical School, Norfolk, VA, USA
    Arch Dermatol 143:239-42. 2007
    ....
  46. pmc Curcuminoids activate p38 MAP kinases and promote UVB-dependent signalling in keratinocytes
    Elias E Ayli
    Department of Dermatology, University of Pennsylvania Medical School, Philadelphia, PA, USA
    Exp Dermatol 19:493-500. 2010
    ..Curcuminoids also synergize with UVB to enhance p53 phosphorylation. The findings provide a rationale for testing curcuminoids in disorders associated with impaired p53 function or in which UVB-treatment is efficacious...
  47. pmc Psoriasis and metabolic disease: epidemiology and pathophysiology
    Rahat S Azfar
    Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Curr Opin Rheumatol 20:416-22. 2008
    ..Increasingly, epidemiological studies are establishing the directionality of these associations and psoriasis' role as an independent risk factor in developing these outcomes...
  48. ncbi request reprint Increased risk for demyelinating diseases in patients with inflammatory bowel disease
    Gauree Gupta
    Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 6021, USA
    Gastroenterology 129:819-26. 2005
    ..However, the underlying relationship between IBD and these neurologic conditions has not been established...
  49. pmc Seeing red: flushing out instigators of niacin-associated skin toxicity
    Richard L Dunbar
    Department of Medicine, Division of Experimental Therapeutics, Institute for Translational Medicine and Therapeutics, Pennsylvania 19104, USA
    J Clin Invest 120:2651-5. 2010
    ..These efforts bring us one step closer to solving a key limitation of an important cardioprotective drug and reveal that the skin response to niacin is much more complicated than previously thought...
  50. doi request reprint High prevalence of aquagenic wrinkling of the palms in patients with cystic fibrosis and association with measurable increases in transepidermal water loss
    Lisa M Arkin
    Department of Pediatrics, Children s Hospital of Philadelphia, Philadelphia, PA 19104, USA
    Pediatr Dermatol 29:560-6. 2012
    ..Aquagenic wrinkling of the palms is prevalent in children with CF and is associated with increased TEWL...
  51. ncbi request reprint Epstein-Barr virus and human herpesvirus type 6 infection in patients with psoriasis
    Andrea L Neimann
    Department of Dermatology, University of Pennsylvania, 3600 Spruce Street, 2 Maloney Building, Philadelphia, PA 19104, USA
    Eur J Dermatol 16:548-52. 2006
    ..11). The results of this study suggest that neither severe psoriasis alone, nor in combination with immunosuppressive therapy, is associated with an increase in Epstein-Barr virus or human herpesvirus 6 replication in white blood cells...
  52. ncbi request reprint The epidemiology of atopic dermatitis
    Ross M Levy
    Department of Dermatology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Clin Dermatol 21:109-15. 2003
  53. doi request reprint Complementary and alternative medicine for psoriasis: a qualitative review of the clinical trial literature
    Nana Smith
    Department of Dermatology, University of Rochester, Rochester, New York, USA
    J Am Acad Dermatol 61:841-56. 2009
    ..Patients with psoriasis often inquire about complementary and alternative medicine in an effort to do everything possible to control the disease...
  54. doi request reprint Use of complementary and alternative medicine among adults with skin disease: results from a national survey
    Nana Smith
    Department of Dermatology, University of Rochester, Rochester, New York 14642, USA
    J Am Acad Dermatol 60:419-25. 2009
    ..Complementary and alternative medicine (CAM) is commonly used for a variety of diseases in the United States. Limited population-based data exist on CAM use among patients with dermatologic conditions..
  55. doi request reprint A randomized, double-blind comparison of the total dose of 1.0% lidocaine with 1:100,000 epinephrine versus 0.5% lidocaine with 1:200,000 epinephrine required for effective local anesthesia during Mohs micrographic surgery for skin cancers
    Pamela A Morganroth
    Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    J Am Acad Dermatol 60:444-52. 2009
    ..We sought to compare total lidocaine dose and patient comfort when using 1.0% lidocaine with 1:100,000 epinephrine versus 0.5% lidocaine with 1:200,000 epinephrine during Mohs micrographic surgery...
  56. pmc Synergistic enhancement of cellular immune responses by the novel Toll receptor 7/8 agonist 3M-007 and interferon-γ: implications for therapy of cutaneous T-cell lymphoma
    Maria Wysocka
    Department of Dermatology, University of Pennsylvania, Philadelphia, PA 19104, USA
    Leuk Lymphoma 52:1970-9. 2011
    ..These results further support our hypothesis that combinations of biological modifiers activating different arms of the immune system may provide significant therapeutic benefits for patients with advanced CTCL...
  57. ncbi request reprint Synthetic imidazoquinolines potently and broadly activate the cellular immune response of patients with cutaneous T-cell lymphoma: synergy with interferon-gamma enhances production of interleukin-12
    Maria Wysocka
    Department of Dermatology, University of Pennsylvania, PA 19104, USA
    Clin Lymphoma Myeloma 7:524-34. 2007
    ....
  58. pmc A prospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativa
    Robert A Lee
    Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    J Am Acad Dermatol 60:565-73. 2009
    ..Medical therapies for hidradenitis suppurativa (HS) are often ineffective. Tumor necrosis factor-alpha inhibitors may be a potential treatment for patients with moderate to severe HS...
  59. pmc Assessing long-term drug safety: lessons (re) learned from raptiva
    Nicole M Seminara
    Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA
    Semin Cutan Med Surg 29:16-9. 2010
    ..Patients and clinicians need to be aware of the relative completeness and limitations of existing safety data of a drug when selecting a treatment...
  60. ncbi request reprint Update on the epidemiology and systemic treatment of psoriasis
    Shanu Kohli Kurd
    Jefferson Medical College, Philadelphia, PA, USA
    Expert Rev Clin Immunol 3:171-85. 2007
    ..In this article, we focus on recent developments in the epidemiology and systemic treatment of psoriasis...
  61. ncbi request reprint The epidemiology of sunburn in the US population in 2003
    Tamu T Brown
    University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    J Am Acad Dermatol 55:577-83. 2006
    ..Sunburn is a major preventable risk factor for skin cancer...
  62. doi request reprint Cardiovascular comorbidities of psoriasis and psoriatic arthritis: a report from the GRAPPA 2012 annual meeting
    April W Armstrong
    Department of Dermatology, University of California Davis, Sacramento, California 95816, USA
    J Rheumatol 40:1434-7. 2013
    ..The panelists also addressed how lessons from CV comorbidity research could be applied to other areas of comorbidity research in psoriasis and PsA and identified future research directions in this area. ..
  63. ncbi request reprint Surrogate endpoints for the treatment of venous leg ulcers
    Joel M Gelfand
    Department of Dermatology and the Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA 19104, USA
    J Invest Dermatol 119:1420-5. 2002
    ....
  64. ncbi request reprint Srcasm overexpression in psoriasis-insights into pathogenesis
    Melissa Pulitzer
    Department of Dermatology, University of Pennsylvania Medical School, Philadelphia, PA, USA
    J Cutan Pathol 34:160-5. 2007
    ..In this study, the levels of Srcasm mRNA and protein are characterized, and the relationship of these experimental observations to the psoriasis pathogenesis is discussed...
  65. ncbi request reprint Association of change in clinical status and change in the percentage of the CD4+CD26- lymphocyte population in patients with Sézary syndrome
    Camille E Introcaso
    Department of Dermatology, The University of Pennsylvania, Philadelphia, Pennsylvania, USA
    J Am Acad Dermatol 53:428-34. 2005
    ..It has been our clinical experience that changes in patients' CD4+CD26- T-cell populations of peripheral blood lymphocytes herald changes in their clinical status...
  66. ncbi request reprint Cross-cultural inequivalence of dermatology-specific health-related quality of life instruments in psoriasis patients
    Tamar Nijsten
    Department of Dermatology, Erasmus MC, Rotterdam, The Netherlands
    J Invest Dermatol 127:2315-22. 2007
    ..Therefore, these instruments should not be used in their current form in international studies...
  67. ncbi request reprint CD8+ lymphoma in a patient with human immunodeficiency virus
    Chad M Hivnor
    Arch Dermatol 141:1321-2. 2005
  68. ncbi request reprint The role of topical therapy for patients with extensive psoriasis
    Steven R Feldman
    Center for Dermatology Research, Wake Forest University School of Medicine, Winston Salem, North Carolina, USA
    Cutis 79:18-31. 2007
    ..Advantages of the 2-compound ointment include rapid onset of action and a relative lack of systemic toxicity. This effective topical agent may expand the psoriasis population that can be considered candidates for topical treatment...
  69. ncbi request reprint Long-term treatment for severe psoriasis: we're halfway there, with a long way to go
    Joel M Gelfand
    Arch Dermatol 143:1191-3. 2007

Research Grants6

  1. Surrogate markers of complete venous ulcer healing
    Joel Gelfand; Fiscal Year: 2002
    ..Through conducting these studies and pursuing the MSCE, the investigator will develop a series of epidemiological tools for which to apply to future scientific investigations. ..
  2. Investigating the Risk of Lymphoma in Psoriasis Patients
    Joel Gelfand; Fiscal Year: 2007
    ....
  3. The Risk of Myocardial Infarction in Patients with Psoriasis
    Joel M Gelfand; Fiscal Year: 2010
    ..Furthermore, to our knowledge, this will be the first analytic study of the risk of stroke in patients with psoriasis, and the first study to examine how psoriasis skin severity impacts the risk of MI. ..
  4. The Risk of Myocardial Infarction in Patients with Psoriasis
    Joel M Gelfand; Fiscal Year: 2010
    ..Furthermore, to our knowledge, this will be the first analytic study of the risk of stroke in patients with psoriasis, and the first study to examine how psoriasis skin severity impacts the risk of MI. ..